In 2023, the Renin-Angiotensin System (RAS) medicines in Italy were forecasted at a benchmark level of 22.4 US dollars per capita. Projections from 2024 through 2028 indicate a consistent value of 22.4 US dollars per capita, suggesting a stagnant market with a 0% compound annual growth rate (CAGR) over this period. This lack of growth may reflect market saturation or stability in demand and competitive pressures, where prices remain flat, potentially offset by any economic factors affecting healthcare expenditures.

Future trends to watch in the Italian RAS market include:

Potential generic drug introductions, which could reduce costs and affect price stability.
Advancements in new treatments or therapies that could shift demand away from traditional RAS medicines.
Healthcare policy changes impacting medication reimbursement or patient access.